Trogenix
PrivateLast Round
Series A
Oct 6, 2025
Total Funding Raised
$114.95M
Company Overview
Trogenix operates in Healthcare & Life Sciences and is based in Edinburgh. Its latest recorded funding round was a Series A round in October 2025.
Trogenix is a biotechnology company that develops precision cancer treatments using its proprietary Odysseus® genetic medicine platform.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Trogenix Comparables
Compare Trogenix with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Siren Biotechnology | 82% | |
| Kopra Bio | 80% | |
| Latus Bio | 79% |
For institutional investors. Book with your work email.
Trogenix Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Oct 6, 2025 | ||||
| Seed | Nov 18, 2024 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Trogenix Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| 4BIO Capital | Series A, Seed |
| Meltwind Advisory | Series A |
| IQ Capital | Seed, Series A |
| LongeVC | Series A |
| Old College Capital | Seed |
| Calculus Capital | Series A |
| Cancer Research Horizons | Seed, Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 23, 2026
Grew 17% QoQ, from 18 to 21 employees.
- May 17, 2026
Grew 18% QoQ, from 17 to 20 employees.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- hiresNov 10, 2026
Trogenix appoints John Young as Chair of the Board, effective immediately, to support its next phase of growth in the United Kingdom on Nov 10th '26.
- hiresNov 10, 2026
Trogenix appoints Josh Murray as Non-Executive Director effective immediately on Nov 10th '26 to support global strategy, commercialisation planning, strategic partnerships and capital markets readiness.
For institutional investors. Book with your work email.
Trogenix Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Trogenix's valuation, stock price, and market status.
Is Trogenix a public or private company?
Trogenix is a private company.
What is the current stock price of Trogenix?
Trogenix is a private company, so its shares have no public market price. Caplight tracks Trogenix's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Trogenix worth (valuation)?
Valuation information for Trogenix is not publicly available.
Can I buy Trogenix stock?
Trogenix shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Trogenix's last funding round?
Trogenix's most recent funding round was Series A on October 6, 2025.
Who are the main investors in Trogenix?
Key investors in Trogenix include 4BIO Capital, IQ Capital.
Will Trogenix IPO soon?
No public IPO plans have been announced for Trogenix.
How can I track Trogenix secondary market activity?
Caplight tracks bids, offers, and trades in Trogenix's shares on secondary markets.